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Background: The level of sustained glycemic control in patients with diabetes mellitus (DM) 
is a major determinant of the occurrence of both acute and chronic complications. However, 
information about the level of glycemic control among patients in the follow-up care at the 
University of Gondar Referral Hospital is scanty. The study assessed the degree of glycemic 
control and associated factors among diabetic patients in the study area.
Method: A hospital-based cross-sectional study was conducted at the University of Gondar 
Referral Hospital. All diabetic patients aged $18 years who visited the Diabetes Clinic in 
January and February 2013 for follow-up medical evaluation and medication participated in the 
study. Patients with glycosylated hemoglobin test (HbA
1c
) of $7% were classified as having 
a poor level of glycemic control. Propensity score was used to estimate the treatment effect. 
 Multivariable logistic regression analysis was applied to determine the associated factors.
Result: Two hundred and fifty three (64.7%) of the 391 diabetic patients included in the study 
had a poor level of glycemic control, as evidenced by HbA
1c
 $7%. Poor glycemic control was 
much higher among Type 1 patients (82.9%) compared with Type 2 patients (57.5%). Being on 
insulin treatment (AOR =2.51; 95% CI =1.25, 5.04) and reporting poor medication adherence 
(AOR =3.19; 95% CI =1.76, 5.80) were found to be associated with poor glycemic control among 
Type 2 DM patients. High waist circumference was inversely associated with a poor level of 
glycemic control in Type 1 DM patients (AOR =0.05; 95% CI =0.01, 0.85).
Conclusion: The proportion of diabetic patients with a poor level of glycemic control is high. 
We recommend a comprehensive intervention to improve the overall treatment adherence with 
special attention to DM patients receiving insulin.
Keywords: glycemic control, HbA
1c
, waist circumference, diabetes mellitus, BMI
Background
Developing countries are currently undergoing one of the most rapid epidemiological 
transitions due to urbanization and changing lifestyles that are associated with the 
increasing occurrence of diabetes mellitus (DM).1 It is a well-known fact that diabetic 
patients can live longer with diabetes and that the occurrence of chronic complications 
that lead to deterioration of the patients’ quality of life and even death can be much 
delayed through access to comprehensive medical care and achieving a sustained level 
of good glycemic control.2 The proper use of effective medications over a sustained 
period and a recommended change of lifestyle have been shown to be crucial for the 
success of glycemic control in the management of DM.3 Adequate diabetes care has 
a wider and more comprehensive scope than merely aiming for glycemic control; 
it also aims at preventing and treating life-threatening end organ damage due to DM. 
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By doing so, adequate diabetes care can prevent premature 
death.4 However, in routine clinical practice in developing 
countries, it is very challenging not only to manage end organ 
damage due to DM but also to achieve sustained glycemic 
control.3
Studies have shown that sustained poor glycemic control 
as defined by glycosylated hemoglobin level (HbA
1c
) $7% is 
a major risk factor for the occurrence of DM-related chronic 
complications. And HbA
1c
 is a simple blood test that provides 
useful information on the average blood glucose control 
over a 6-to-12-week period.3,5–7 Despite the fact that DM is 
believed to be an emerging and huge health care challenge in 
developing countries, very little has been studied about the 
Ethiopian situation to help policy makers and stakeholders 
initiate evidence-based planning and suitable interventions 
to combat DM. We conducted a cross-sectional study to 
assess the level of glycemic control and its associated factors 
among DM patients receiving diabetes care at the University 
of Gondar Referral Hospital.
Methods
A hospital-based cross-sectional design was used for the 
study. The hospital has a Diabetes Illness Follow-up Care 
Clinic, which was organized 2 decades ago and currently 
provides free service for more than 8,000 diabetic patients on 
a follow-up basis. We chose the 2-month follow-up schedule 
for data collection to avoid repetition of the cases as patients 
revisit the clinic every 2 months.
Study population
All diabetic patients aged $18 years who visited the Clinic 
in January and February 2013 for control of blood sugar and 
medication were invited to participate in the study. Also, 
patients who were on follow-up for $12 months were included 
in the study as adequate time was needed for assessing adher-
ence. On the other hand, those who were critically ill and 
unable to participate in the interview and also those who were 
recently diagnosed and had a follow-up of ,12 months were 
excluded. About 1,000 diabetic patients visited the Clinic in 
the 2 month period. Every second person aged $18 years was 
included. Thus, a total of 407 study subjects were selected 
through a systematic sampling procedure.
Data collection
Data were collected by interviewing eligible participants 
using a pretested and structured questionnaire. Patients were 
given an orientation on the protocol and specific details 
 concerning participation in the study. The questionnaire, 
which was in the local language (Amharic), included 
questions that assessed diabetes-related factors (background 
information, lifestyle factors, clinical history, and medication 
adherence using the eight-item Morisky medication adher-
ence scale [MMAS-8]).3,4 Anthropometric measurements 
were taken using standardized techniques and calibrated 
equipment. Patients were weighed to the nearest 0.1 kg in 
light indoor clothing and bare feet or with stockings. Height 
was measured using a stadiometer; waist girth was measured 
by placing a plastic tape to the nearest 0.5 cm horizontally, 
midway between the 12th rib and the iliac crest on the 
midaxillary line. Hip circumference was measured around 
the widest portion of the buttocks, with the tape parallel to 
the floor. Finally, biochemical tests (HbA
1c
, FBG, triglyceride, 
and total cholesterol test) were carried out.5
Blood samples were collected from each participant by a 
trained laboratory technician following aseptic techniques. 
The blood samples were taken to the hospital laboratory for 
chemistry analyses immediately. Biochemical tests (HbA
1c
) 
were carried out using a 902 Automatic Analyzer with 
Roche/Hitachi kit following a minimum of 8 hours’ fasting. 
Information about the Type 1 and Type 2 DM was collected 
from the hospital chart by the study nurse.
Six laboratory technicians, four nurses, and two supervi-
sors were trained by the principal investigator. Every patient 
was made aware of the fasting requirement for a minimum 
of 8 hours prior to the lab test. A reminder was sent to them 
prior to the day of investigation, verbal confirmation of which 
was obtained prior to the blood test. The study supervisors 
and the principal investigator conducted regular supervisory 
checks to ensure data quality. Data entry and cleaning were 
done using Epi-info version 3.5.3.
Data analysis
Glycemic control was calculated on the basis of test results 
(HbA
1c
 $7.0%) by type of diabetes (Type 1 and 2) and 
stratified by residence (urban and rural). In the multivari-
able analysis, diabetic patients with good glycemic control 
(HbA
1c
 ,7.0%) and those with poor glycemic control 
(HbA
1c
 $7.0%)6,7 were compared to identify potential risk 
factors.8
BMI was used to define underweight (BMI ,18.5), nor-
mal (18.5# BMI ,25.0), overweight (25.0# BMI ,30.0), 
and obesity (BMI $30) adults. On the basis of their waist 
circumference (WC) measurements, patients were classi-
fied, according to cutoffs recommended by the WHO, into 
three health risk categories: low risk (men, WC =93.9 cm 
or less; women, WC =79.9 cm or less); increased risk (men, 
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WC =94.0–101.9 cm; women, WC =80.0–87.9 cm); and high 
risk (men, WC =102.0 cm or more; women, WC =88.0 cm 
or more) for DM.9 A wealth score was computed, using 
principal component analysis (PCA), from 16 variables that 
included monthly income, agricultural productivity, fixed 
asset, household assets, and utility; and the assumption of 
PCA was checked.
The propensity score was used for the estimation of 
treatment effect of nonadherence to poor glycemic control. 
We stratified the analysis in terms of DM type in the mul-
tiple regressions. The results were considered statistically 
significant at P#0.05. Multivariable logistic regression 
analysis was applied to determine the associations of risk 
factors. The independent variables were included in the 
model on the basis of prior evidence in the literature and 
their effect in current analysis. Independent variables with 
a P-value of 0.20 and less, during the bivariate test, were 
included.
ethical statement
The protocol was approved by the IRB of the University of 
Gondar. In addition, written permission was obtained from 
the Hospital Director to extract relevant information from the 
medical record. Participants were recruited on a voluntary 
basis after full information about the research was provided 
and a written consent agreement signed.
Results
A total of 407 diabetic patients were invited to participate 
in this study; 16 declined to participate, yielding a response 
rate of 96.01% (391 out of 407). The mean age (± SD) of 
the persons with diabetes was 50.4 (±15.2) years. The mean 
age (± SD) for Type 1 DM was 35.8 (±13.4) and 56.1 (±11.5) 
for Type 2. There was a slight preponderance of males (53%) 
over females (47%). (Sociodemographic characteristics are 
presented in Tables 1 and 2).
The mean (± SD) percentage of glycated hemoglobin 
test (HbA
1c
) was 7.82 (±1.9) (Table 3). The overall preva-
lence of poor glycemic control in persons with diabetes 
was 64.7% (95% CI =59.9, 69.4). The prevalence of poor 
glycemic control was significantly higher among Type 1 
diabetics; the proportion with poor glycemic control was 
82.9% (95% CI =75.8, 89.9) among Type 1 and 57.5% (95% 
CI =51.7, 63.3) among Type 2 DM patients. Poor glycemic 
control was higher among rural compared with urban dwell-
ers; the proportion with poor glycemic control was 86.4% 
(95% CI =76.1, 96.6) and 61.9% (95% CI =56.8, 67.1) among 
rural and urban dwellers, respectively (Figure 1).
The attributable risk effect estimation of medication 
adherence using the propensity score showed that medication 
nonadherence had an effect on poor glycemic control, and 
the risk difference between nonadherence and good medical 
adherence for poor glycemic control was high among Type 2 
diabetics (23.8%), (95% CI =12, 35) (t=4.14). Similarly, in 
Table 1 Sociodemographic and clinical characteristics of the 
study population by type of diabetes attending diabetic follow-up 
clinic in gondar referral hospital, ethiopia, 2013
Variable n (%) Type 1 person  
with diabetes,  
n (%)
Type 2 person 
with diabetes, 
n (%)
age in years
 #24 29 (7.4) 27 (93.1) 2 (6.9)
 25–44 98 (25.1) 59 (60.2) 39 (39.8)
 45–64 191 (48.9) 20 (10.5) 171 (89.5)
 $65 73 (18.7) 5 (6.9) 68 (93.2)
Sex
 Female 207 (52.9) 40 (19.3) 167 (80.7)
 Male 184 (47.1) 71 (38.6) 113 (61.4)
residence
 rural 44 (11.2) 33 (75) 11 (25)
 Urban 347 (88.8) 78 (22.5) 269 (77.5)
religion
 Orthodox 332 (84.9) 101 (30.4) 231 (69.6)
 Muslim 54 (13.8) 9 (16.7) 45 (83.3)
 Other 5 (1.3) 1 (20) 4 (80)
Family size
 #4 165 (42.2) 54 (32.7) 111 (67.3)
 5–8 193 (49.4) 53 (27.5) 140 (72.5)
 $9 33 (8.4) 4 (12.1) 29 (87.9)
Duration of diabetes
 ,7 years 204 (52.6) 54 (26.5) 150 (73.5)
 $7 years 184 (47.4) 56 (30.4) 128 (69.6)
Triglyceride
 normal (,200) 240 (61.4) 92 (38.3) 148 (61.7)
 high (200–499) 145 (37.1) 16 (11) 129 (88.9)
 Very high ($500) 6 (1.5) 3 (50) 3 (50)
Total cholesterol
 normal (#250) 373 (95.4) 110 (29.5) 263 (70.5)
 high ($251) 18 (4.6) 1 (5.6) 17 (94.5)
Wealth index
 Poor 135 (34.5) 76 (56.3) 59 (43.7)
 Medium 118 (30.2) 22 (18.6) 96 (81.4)
 rich 138 (35.3) 13 (9.4) 125 (90.6)
Medication adherence
 low 99 (25.4) 31 (31.3) 68 (68.7)
 Medium 112 (28.7) 33 (29.5) 79 (70.5)
 high adherence 179 (45.9) 47 (26.3) 132 (73.4)
Waist circumference (Wc)
 low risk 144 (36.9) 81 (56.2) 63 (43.8)
 increased risk 99 (25.4) 14 (14.1) 85 (85.9)
 high risk 147 (37.7) 16 (10.9) 131 (89.1)
insulin therapy
 no 192 (49.1) 3 (1.6) 189 (98.4)
 Yes 199 (50.9) 108 (54.3) 91 (45.7)
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the multiple regressions analysis, diabetics who reported poor 
medication adherence were three times more likely to have 
poor glycemic control (AOR =3.19; 95% CI =1.76, 5.80) 
among Type 2 diabetic patients (Table 2).
The reported follow-up visit for the last 6 months showed 
that increased frequency of hospital visits was negatively asso-
ciated with poor glycemic control (AOR =0.13; 95% CI =0.03, 
0.59) among persons with Type 2 diabetes. The occurrence 
of poor level of glycemic control was 7.6 times more likely 
in individuals who had no follow-up visits compared with 
those who had four visits in the last 6 months.  Individuals 
receiving insulin treatment (AOR =2.51; 95% CI =1.25, 5.04) 
had significant association with poor glycemic control, among 
subjects with Type 2 DM.
Hundred and forty seven (37.7%) of the diabetic patients 
had a high-risk score of WC using the threshold of $92 cm 
Table 2 Multivariate analysis of factors associated with poor glycemic control among persons with type of diabetes in gondar referral 
hospital of gondar, north West ethiopia (2013)
Variable n Poor glycemic  
control cases, n (%)
Adjusted OR [95% CI]
Type 1 diabetes Type 2 diabetes
age in years
 #24 29 25 (86.2) 1 1
 25–44 97 76 (78.4) 1.13 [0.15, 8.32] 0.74 [0.02, 25.8]
 45–64 188 119 (63.3) 0.63 [0.05, 8.22] 0.89 [0.03, 27.9]
 $65 73 32 (43.8) 0.28 [0.01, 5.96] 0.39 [0.01, 12.9]
Wealth index
 Poor 135 106 (78.5) 1 1
 Medium 118 61 (51.7) 0.53 [0.07, 3.91] 0.54 [0.24, 1.23]
 rich 138 86 (62.3) 0.63 [0.06, 6.81] 0.87 [0.39, 1.94]
Medication adherence
 adherence 179 98 (54.8) 1 1
 nonadherence 211 154 (73.0) 2.1 [0.48, 9.29] 3.19 [1.76, 5.80]
Duration of diabetes
 ,7 years 230 133 (57.8) 1 1
 $7 years 158 118 (74.7) 2.71 [0.49, 14.9] 1.59 [0.82, 3.10]
Waist circumference
 low risk 144 112 (77.8) 1 1
 increased risk 99 60 (60.6) 0.60 [0.06, 6.13] 1.13 [0.50, 2.54]
 high risk 147 80 (54.4) 0.05 [0.01, 0.85] 0.64 [0.28, 1.46]
insulin therapy
 no 192 99 (51.6) 1 1
 Yes 199 154 (77.4) 0.72 [0.01, 56.6] 2.51 [1.25, 5.04]
Sex
 Male 184 125 (67.9) 1 1
 Female 207 128 (61.8) 1.39 [0.21, 9.16] 1.70 [0.87, 3.29]
residence
 Urban 347 215 (61.9) 1 1
 rural 44 38 (86.4) 0.45 [0.06, 3.30] 1.03 [0.19, 5.16]
Moderately physically active
 Yes 256 174 (67.9) 1 1
 no 129 75 (58.1) 2.74 [0.39, 19.12] 1.16 [0.64, 2.11]
cigarette smoking
 no 382 245 (64.1) 1 –
 Yes 9 8 (88.9) 1.46 [0.001, 225] –
hypertension
 no 211 155 (73.5) 1 1
 Yes 180 98 (54.4) 5.89 [0.88, 39.5] 1.02 [0.55, 1.92]
Follow-up visit in the last 6 months
 no visit 19 11 (57.9) 1 1
 2–3 315 167 (53.0) 4.58 [0.16, 125] 0.38 [0.09, 1.44]
 More than 45 27 (60.0) 18.9 [0.23, 1,574] 0.13 [0.03, 0.59]
Dyslipidemia
 no 322 75 (23.3) – 1
 Yes 69 41 (59.4) – 1.64 [0.49, 5.51]
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Figure 1 Proportion of glycemic control by residence and sex among person with diabetes, with 95% ci error bar at gondar referral hospital, north West ethiopia in 2013.
Table 3 Univariate analyses of factors associated with poor 
glycemic control using the mean hba1c among patients with DM 
at gondar referral hospital, ethiopia (2013)
Variable n (%) Mean  
(Std Err)
95% CI P-value
age in years
 #24 29 (7.4) 9.4 (0.44) [8.54, 10.26]
 25–44 97 (24.8) 8.4 (0.21) [7.99, 8.81] P,0.001
 45–64 190 (48.6) 7.6 (0.12) [7.36, 7.82]
 $65 73 (18.7) 7 (0.18) [6.65, 7.35]
Sex
 Female 207 (52.9) 7.58 (0.12) [7.35, 7.82] P=0.010
 Male 184 (47.1) 8.08 (0.15) [7.78, 8.38]
Type of diabetes
 Type 1 111 (28.4) 8.66 (0.20) [8.26, 9.07] P,0.001
 Type 2 280 (71.6) 7.48 (0.10) [7.29, 7.68]
Duration of diabetes
 ,7 years 230 (59.3) 7.68 (0.14) [7.41, 7.96] P=0.136
 $7 years 158 (40.7) 7.97 (0.13) [7.71, 8.23]
Abbreviations: DM, diabetes mellitus; Std err, standard error; hba1c, glycosylated 
hemoglobin level; CI, confidence interval.
for women and $104 cm for men. The multivariate logistic 
regression revealed that the high WC was inversely associ-
ated with poor glycemic control compared with the low 
WC among Type 1 persons with diabetes (AOR =0.05; 
95% CI =0.01, 0.85). WC had no significant association 
with poor glycemic control among subjects with Type 2 DM 
(Table 2). The duration of diabetes was also positively associ-
ated with poor glycemic control (AOR =2.17; 95% CI =1.22, 
3.85). Those who had been diagnosed with DM for more than 
7 years were twice as likely to have poor glycemic control 
as those who had diabetes for less than 7 years.
Discussion
In this study, we were able to measure objectively the pro-
portion of poor glycemic control and its associated factors 
in diabetic patients. Poor glycemic control, as defined by 
HbA
1c
 $7%, was higher in persons with Type 1 diabetes, 
among rural dwellers, and insulin-treated Type 2 diabetics. 
The risk factors for poor glycemic control in Type 2 DM 
included poor medication adherence, being on insulin treat-
ment, and having a poor record of follow-up visits during the 
last 6 months. High WC was found to be inversely associated 
with poor glycemic control in Type 1 DM patients.
The glycemic control level found in this study was similar 
to a previous estimation in Africa but lower than (82.7%) that 
found in studies in Jimma.10–12 The discrepancy between the 
findings of the study done in Jimma and those of this study 
can be explained by the fact that our study used the recom-
mended test for glycemic control, the HbA
1c
 test, whereas 
the Jimma study used the fasting blood sugar (FBS) test for 
diagnosis.13 Moreover, the Jimma study included only Type 
1 DM patients on insulin.
The increased occurrence of poor glycemic control 
among Type 1 diabetics in rural parts of Ethiopia was con-
sistent with the findings of previous studies.11,14 In our study, 
a high level of poor glycemic control was noted among 
Type 2 DM patients on insulin treatment. The findings are 
consistent with those of other studies.14,15 The use of insulin 
among Type 2 diabetics often reflects disease severity, and 
it is also possible that persons with Type 2 diabetes treated 
with insulin are more difficult to control because of the risk 
of setting up a vicious cycle of increasing weight, adjusting 
insulin doses, and increasing insulin resistance, with conse-
quent deterioration in glycemic control.16,17 In our finding, 
insulin-treated Type 2 diabetics were overweight (a mean 
BMI of 27.5 kg/m2), which may contribute to the observed 
rise in poor glycemic levels among the insulin-treated Type 2 
persons with diabetes.15
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The risk difference for poor glycemic control between 
good treatment adherence and nonadherence was found to 
be high; poor glycemic control was common among those in 
the nonadherence group. This finding is consistent with other 
reports in Jordan and Malaysia.3,15 Literature shows that low 
treatment adherence continues to be a considerable barrier 
that prevents many diabetics from achieving good glycemic 
control. Increased compliance is associated with substantial 
improvements in glycemic control in health care.13 The 
challenge of managing multiple prescriptions and a reduced 
sense of urgency owing to asymptomatic conditions among 
Type 2 DM patients, patients’ understanding of their disease 
condition, and traditional beliefs in the rural community may 
affect adherence. Similarly, studies have also shown that DM 
patients with adequate knowledge of their status who regu-
larly attend clinic and receive regular counseling are more 
likely to have better adherence.18,19 Continuous education is 
important in motivating patients to cultivate healthy lifestyles 
and maintain good treatment adherence.15,20 Besides, it is 
common for patients to improve their medication-taking 
behavior shortly before and after appointments with health 
care providers.21
Our study also showed a significant association between 
low WC and poor level of glycemic control among Type 1 
diabetic patients. One of the plausible explanations for such 
an association is that the strict adherence among insulin-
treated persons might have increased body weight and WC. 
Moreover, individuals who wanted to gain weight were 
highly likely to be adherent to treatment regimens among 
Type 1 DM, and this might have contributed to the observed 
good level of glycemic control among Type 1 DM patients 
with high WC compared with low WC.22
The limitation of this research was that we used a smaller 
sample size in view of the high cost of HbA
1c
, which affected 
our analysis when we stratified further in terms of diabetes 
type. Associated factors of poor glycemic control were 
hospital-based using a cross-sectional design, which might 
not show temporal relationships with potential risk factors. 
Longitudinal research is needed to assess the relationship 
between the variables over time.
Conclusion
The occurrence of poor levels of glycemic control was 
found to be higher in Type 1 DM patients, insulin-taking 
Type 2 DM patients, and rural dwellers. Moreover, reported 
nonadherence to medication regimens was common, and 
it substantially contributed to the poor level of glycemic 
control in the setting. We recommend that the health system 
be equipped with adequate and sustainable diagnostic tools, 
including the HbA
1c
 test for proper monitoring of glyce-
mic control. Sustainable insulin supply for insulin-taking 
DM patients and a facilitated referral system for patients 
with complications could also help improve the situation. 
Stakeholders should also consider upgrading the capacity 
of the tertiary hospitals by providing advanced diabetes 
care for end organ damage that inevitably follows poor 
glycemic control.
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